Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Wuxi AppTec Co's Sloan Ratio for the quarter that ended in Mar. 2026 was 11.05%.
As of Mar. 2026, Wuxi AppTec Co has a Sloan Ratio of 11.05%, indicating there is a warning stage of accrual build up.
Wuxi AppTec Co (OTCPK:WUXIF) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, Wuxi AppTec Co has a Sloan Ratio of 11.05%, indicating there is a warning stage of accrual build up.
Wuxi AppTec Co Sloan Ratio % Related Terms
Wuxi AppTec Co Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Wuxi AppTec Co's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Wuxi AppTec Co's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co Sloan Ratio % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Wuxi AppTec Co's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Wuxi AppTec Co's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was 680.87 (Jun. 2025 ) + 493.385 (Sep. 2025 ) + 1004.525 (Dec. 2025 ) + 674.906 (Mar. 2026 ) = $2,854 Mil.
Wuxi AppTec Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was 589.877 (Jun. 2025 ) + 558.974 (Sep. 2025 ) + 822.116 (Dec. 2025 ) + 521.729 (Mar. 2026 ) = $2,493 Mil.
Wuxi AppTec Co's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was -54.344 (Jun. 2025 ) + -197.175 (Sep. 2025 ) + -333.666 (Dec. 2025 ) + -776.014 (Mar. 2026 ) = $-1,361 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuxi AppTec Co (WUXIF) has a Sloan Ratio % of 11.05% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Wuxi AppTec Co and its competitors.
Is Wuxi AppTec Co's Sloan Ratio % too high?
Wuxi AppTec Co's current Sloan Ratio % is 11.05%. Overall, Wuxi AppTec Co has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's Sloan Ratio % compare to TMO and DHR?
Wuxi AppTec Co's Sloan Ratio % of 11.05% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Diagnostics & Research company?
A good Sloan Ratio % depends on the Medical Diagnostics & Research industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Wuxi AppTec Co and its competitors. Wuxi AppTec Co's current Sloan Ratio % is 11.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (WUXIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $14.70, compared to a current price of $21.55 — trading 46.6% above its estimated fair value. The current Sloan Ratio % is 11.05%. Wuxi AppTec Co's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Wuxi AppTec Co (WUXIF), the current Sloan Ratio % is 11.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (WUXIF) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of $21.55 is trading 46.6% above its estimated GF Value™ of $14.70.
GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.
Key valuation signals for WUXIF:
Sloan Ratio %: 11.05%
GF Value™: $14.70 vs. price of $21.55 (46.6% above fair value)
No single metric tells the full story. See the WUXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
81GF Score
Get the complete analysis for WUXIF
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WUXIF has been successfully added to your 
